회사 개요
United Therapeutics Corporation is a leading entity within the healthcare sector, specifically operating in the drug manufacturing industry focused on specialty and generic pharmaceuticals, where it develops and commercializes products to address unmet medical needs for patients suffering from chronic and life-threatening diseases in the United States and internationally. The company's primary product offering includes Tyvaso DPI, an inhaled dry powder administered via pre-filled and single-use canisters, which targets conditions such as pulmonary hypertension. As of the latest data, United Therapeutics holds a substantial market capitalization of $25.49B and generates annual revenue of $3.18B based on trailing twelve-month figures. With an employee count of 1,400, the company demonstrates a significant operational scale that positions it as a major player in the specialized pharmaceutical landscape. These valuation metrics indicate a large enterprise with a robust revenue base, reflecting its established market position and the high value investors place on its proprietary drug portfolio and global commercialization capabilities.
재무 건전성
United Therapeutics reported a trailing twelve-month revenue of $3.18B, with a corresponding net income of $1.33B and an EBITDA of $1.60B, illustrating a financial structure where operating costs and taxes significantly reduce the bottom line from gross earnings. The gap between the $3.18B revenue and the $1.33B net income reveals a cost structure that maintains high profitability while absorbing substantial expenses related to research, development, and commercialization inherent to the drug manufacturing industry. The company generates a robust free cash flow of $582.01M, which provides exceptional financial flexibility to fund future research initiatives, pursue strategic acquisitions, or navigate economic downturns without compromising operational continuity. Profitability analysis shows a gross margin of 87.9%, indicating highly efficient production and pricing power typical of patented specialty drugs, alongside an operating margin of 45.0% and a profit margin of 41.9% that highlight strong control over overhead and tax burdens. On the balance sheet, the company holds $2.92B in cash against a negligible debt load of $37.60M, resulting in a conservative debt-to-equity ratio of 0.53 that underscores a low-risk leverage profile. This conservative stance is further supported by a current ratio of 6.61, which signals an overwhelming ability to meet short-term obligations with liquid assets, ensuring high short-term liquidity. Management effectiveness is further evidenced by a Return on Equity of 19.7% and a Return on Assets of 12.4%, metrics that demonstrate efficient utilization of shareholder capital and asset base to generate substantial returns.
밸류에이션 평가
The valuation of United Therapeutics can be analyzed through its trailing P/E ratio of 20.88 and forward P/E of 17.09, where the difference between these two figures implies that the market expects earnings growth to accelerate, leading to a lower multiple in future periods relative to current performance. The price-to-book ratio stands at 3.58, indicating that the market prices the company at a significant premium over its tangible book value, likely due to the intangible value of its intellectual property and regulatory approvals. Alternative valuation metrics such as a price-to-sales ratio of 8.01 and an EV/EBITDA of 14.12 suggest that investors are willing to pay a high multiple for sales and earnings, reflecting confidence in the company's pricing power and future cash generation capabilities. In terms of price action, the stock has traded within a 52-week range between a low of $266.98 and a high of $607.89, with the current trading price sitting at a specific point within this historical volatility band that reflects recent market sentiment. The company's beta of 0.75 indicates that its stock price is less volatile than the broader market, moving with lower sensitivity to general market fluctuations and offering a relatively stable risk profile compared to high-beta biotechnology peers.
Growth & Income
United Therapeutics is demonstrating strong fundamental expansion with a revenue growth rate of 7.4% and an earnings growth rate of 24.5% year-over-year, where the significantly higher earnings growth rate implies that the company is successfully scaling its operations and improving its profit margins faster than its top line is expanding. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning that instead of distributing cash to shareholders, the firm retains all its earnings to reinvest into new drug development, clinical trials, and market expansion strategies. This strategy of retaining earnings rather than paying dividends aligns with the capital-intensive nature of pharmaceutical R&D, allowing the company to leverage its $2.92B cash position to fuel long-term growth without relying on external equity financing. The overall growth and income profile of United Therapeutics is characterized by aggressive earnings expansion and a complete focus on capital reinvestment, positioning the company for potential future value creation through organic growth and pipeline advancement rather than current income distribution.